日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

维奈托克、苯达莫司汀和利妥昔单抗治疗复发或难治性非霍奇金淋巴瘤患者:一项 Ib 期剂量探索研究

de Vos, S; Swinnen, L J; Wang, D; Reid, E; Fowler, N; Cordero, J; Dunbar, M; Enschede, S H; Nolan, C; Petrich, A M; Ross, J A; Salem, A H; Verdugo, M; Agarwal, S; Zhou, L; Kozloff, M; Nastoupil, L J; Flowers, C R

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

新型靶向药物治疗慢性淋巴细胞白血病引起的肿瘤溶解综合征

Cheson, Bruce D; Heitner Enschede, Sari; Cerri, Elisa; Desai, Monali; Potluri, Jalaja; Lamanna, Nicole; Tam, Constantine

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

使用维奈托克靶向BCL2治疗复发性慢性淋巴细胞白血病

Roberts, Andrew W; Davids, Matthew S; Pagel, John M; Kahl, Brad S; Puvvada, Soham D; Gerecitano, John F; Kipps, Thomas J; Anderson, Mary Ann; Brown, Jennifer R; Gressick, Lori; Wong, Shekman; Dunbar, Martin; Zhu, Ming; Desai, Monali B; Cerri, Elisa; Heitner Enschede, Sari; Humerickhouse, Rod A; Wierda, William G; Seymour, John F

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

一项评估BCL2抑制剂navitoclax联合利妥昔单抗治疗复发或难治性CD20+淋巴瘤患者的安全性、药代动力学和抗肿瘤活性的I期研究

Roberts, Andrew W; Advani, Ranjana H; Kahl, Brad S; Persky, Daniel; Sweetenham, John W; Carney, Dennis A; Yang, Jianning; Busman, Todd B; Enschede, Sari H; Humerickhouse, Roderick A; Seymour, John F

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

ABT-199 是一种强效选择性 BCL-2 抑制剂,可实现抗肿瘤活性,同时保护血小板

Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron, Jun Chen, Brian D Dayton, Hong Ding, Sari H Enschede, Wayne J Fairbrother, David C S Huang, Sarah G Hymowitz, Sha Jin, Seong Lin Khaw, Peter J Kovar, Lloyd T Lam, Jackie Lee, Heather L Maecker, Kennan C Marsh, Ky

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

慢性淋巴细胞白血病对 BCL2 抑制剂具有显著敏感性:navitoclax 治疗复发或难治性疾病患者的 I 期研究结果

Roberts, Andrew W; Seymour, John F; Brown, Jennifer R; Wierda, William G; Kipps, Thomas J; Khaw, Seong Lin; Carney, Dennis A; He, Simon Z; Huang, David C S; Xiong, Hao; Cui, Yue; Busman, Todd A; McKeegan, Evelyn M; Krivoshik, Andrew P; Enschede, Sari H; Humerickhouse, Rod

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

一项针对新型 Bcl-2 家族抑制剂 Navitoclax (ABT-263) 的 I 期研究,旨在评估其在小细胞肺癌和其他实体瘤患者中的疗效。

Gandhi, Leena; Camidge, D Ross; Ribeiro de Oliveira, Moacyr; Bonomi, Philip; Gandara, David; Khaira, Divis; Hann, Christine L; McKeegan, Evelyn M; Litvinovich, Elizabeth; Hemken, Philip M; Dive, Caroline; Enschede, Sari H; Nolan, Cathy; Chiu, Yi-Lin; Busman, Todd; Xiong, Hao; Krivoshik, Andrew P; Humerickhouse, Rod; Shapiro, Geoffrey I; Rudin, Charles M

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Navitoclax,一种靶向高亲和力BCL-2抑制剂,在淋巴系统恶性肿瘤中的应用:一项评估其安全性、药代动力学、药效学和抗肿瘤活性的I期剂量递增研究

Wilson, Wyndham H; O'Connor, Owen A; Czuczman, Myron S; LaCasce, Ann S; Gerecitano, John F; Leonard, John P; Tulpule, Anil; Dunleavy, Kieron; Xiong, Hao; Chiu, Yi-Lin; Cui, Yue; Busman, Todd; Elmore, Steven W; Rosenberg, Saul H; Krivoshik, Andrew P; Enschede, Sari H; Humerickhouse, Rod A